Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib for patients with unresectable liver metastasis, who had progressed after, or were refractory to first- or later-line therapy.

Trial Details

NCT ID

NCT05098847

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Sintilimab
Lenvatinib
Cryoablation

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Written informed consent obtained.
Age ≥ 18 years at time of study entry.
Participants must have unresectable liver metastasis from solid tumors.
Participants must have progressed after, or were refractory to first- or later-line therapy in the liver metastatic setting.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →